(Q36392233)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

review article

0 references

title

Al amyloidosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

24 March 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Sébastien Bender

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Arnaud Jaccard

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

9

Jean-Michel Goujon

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

7

Nathalie Quellard

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Estelle Desport

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Frank Bridoux

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Sébastien Delbes

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Béatrice Fernandez

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Corinne Lacombe

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

David Lavergne

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Julie Abraham

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Guy Touchard

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Jean-Paul Fermand

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Centre national de référence pour l’amylose AL et les autres maladies par dépôts d’immunoglobulines monoclonales

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

21 August 2012

2 references

24 March 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

Orphanet Journal of Rare Diseases

11 February 2020

published in

2 references

24 March 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 2.0 Generic

11 February 2020

copyright license

1 reference

on focus list of Wikimedia project

24 March 2019

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Cardiac amyloidosis: a practical approach to diagnosis and management

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Amyloidosis: pathogenesis and new therapeutic options.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Amyloid diseases of the heart: assessment, diagnosis, and referral

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Amyloidosis-where are we now and where are we heading?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Transplantation for IgM amyloidosis and IgM myeloma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Evaluation and management of the cardiac amyloidosis.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

New insights into systemic amyloidosis: the importance of diagnosis of specific type

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

The spectrum of localized amyloidosis: a case series of 20 patients and review of the literature

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Prevalence of monoclonal gammopathy of undetermined significance

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Localized amyloidosis: a survey of 35 French cases

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Clinical aspects of systemic amyloid diseases.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Molecular mechanisms of amyloidosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Hereditary systemic amyloidosis with renal involvement.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Diagnostic tools for amyloidosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Primary localized amyloidosis of the urinary bladder: a case series of 31 patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Common core structure of amyloid fibrils by synchrotron X-ray diffraction.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Use of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Structure of a monoclonal kappa chain of the V kappa IV subgroup in the kidney and plasma cells in light chain deposition disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Amyloidosis: review of 236 cases

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Radiologic findings in renal amyloidosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Atypical amyloidosis: diagnostic challenges and the role of immunoelectron microscopy in diagnosis

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Guidelines on the diagnosis and management of AL amyloidosis

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test?

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Renal monoclonal immunoglobulin deposition disease: the disease spectrum

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495844

Renal Monoclonal Immunoglobulin Deposition Disease: A Report of 64 Patients from a Single Institution

21 September 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-7-54

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-7-54

The protofilament substructure of amyloid fibrils11Edited by F. E. Cohen

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-7-54

Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-7-54

Outcome in Renal AL Amyloidosis After Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-7-54

Outcome of autologous stem cell transplantation for AL amyloidosis in the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-7-54

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-7-54

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-7-54

Solid Organ Transplantation in AL Amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-7-54

Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1750-1172-7-54

Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay

21 January 2018

1 reference

12 December 2020

Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis

1 reference

12 December 2020

Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool

1 reference

12 December 2020

Renal transplantation in light chain amyloidosis: coming out of the cupboard

1 reference

12 December 2020

Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis

1 reference

12 December 2020

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine

1 reference

12 December 2020

Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients

1 reference

12 December 2020

Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone

1 reference

12 December 2020

Preferential expression of human lambda-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenström's macroglobulinemia

1 reference

12 December 2020

The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients

1 reference

12 December 2020

High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study

1 reference

12 December 2020

Increased plasmin-α2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses

1 reference

12 December 2020

Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients

1 reference

12 December 2020

Doppler Myocardial Imaging Compared to Standard Two-Dimensional and Doppler Echocardiography for Assessment of Diastolic Function in Patients With Systemic Amyloidosis

1 reference

12 December 2020

Identifiers

DOI

10.1186/1750-1172-7-54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

11 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

PubMed publication ID

22909024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22909024%20AND%20SRC:MED&resulttype=core&format=json